FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody against LAG-3 or its antigen-binding fragment. A molecule of isolated nucleic acid encoding the specified antibody; an expression vector containing the specified nucleic acid molecule; a host cell containing the specified vector; a pharmaceutical composition containing the specified antibody are also disclosed. Methods for the treatment using the specified antibody and inhibition of growth of tumor cells related to LAG-3; the use of the specified antibody for the preparation of a drug for the treatment of a disease related to overexpression of LAG-3 are disclosed.
EFFECT: invention has the capability of the effective treatment of diseases related to LAG-3.
25 cl, 5 ex, 15 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
